Treatment of chronic hepatitis B;Traitement de l'hépatite chronique B

Gastroenterologie Clinique et Biologique

Volumn 32, Issue 8-9, 2008, Pages 749-768

  Asselah, T ^a   Lada, O ^a   Boyer, N ^a   Martinot, M ^a   Marcellin, P ^a  

^a CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ALPHA2B INTERFERON; CLEVUDINE; EMTRICITABINE; ENTECAVIR; FAMCICLOVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PLACEBO; PRADEFOVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; VALTORCITABINE;

ANTIVIRAL RESISTANCE; CHRONIC HEPATITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; HEPATITIS B; HUMAN; MONOTHERAPY; SEROCONVERSION; SHORT SURVEY; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VIRUS REACTIVATION;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEPATITIS B, CHRONIC; HUMANS; INTERFERONS;

EID: 51749110906     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gcb.2008.07.001     Document Type: Short Survey

References (130)

1. Ganem D., and Prince A.M. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 350 (2004) 1118-1129
2. Bonilla Guerrero R., and Roberts L.R. The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma. J Hepatol 42 (2005) 760-777
3. Marcellin P., and Lada O. Prise en charge de la résistance aux antiviraux dans le traitement de l'hépatite chronique B. Gastroenterol Clin Biol 30 (2006) 3S5-13S
4. Lok A.S., and McMahon B.J. Chronic hepatitis B. Hepatology 45 (2007) 507-539
5. Hoofnagle J.H., Doo E., Liang T.J., Fleischer R., and Lok A.S. Management of hepatitis B: summary of a clinical research workshop. Hepatology 45 (2007) 1056-1075
6. Wong D.K., Cheung A.M., O'Rourke K., Naylor C.D., Detsky A.S., and Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 119 (1993) 312-323
7. Cooksley W.G., Piratvisuth T., Lee S.D., Mahachai V., Chao Y.C., Tanwandee T., et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 10 (2003) 298-305
8. Lau G.K., Piratvisuth T., Luo K.×., Marcellin P., Thongsawat S., Cooksley G., et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352 (2005) 2682-2695
9. Janssen H.L., van Zonneveld M., Senturk H., Zeuzem S., Akarca U.S., Cakaloglu Y., et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365 (2005) 123-129
10. Asselah T., Ripault M.P., Castelnau C., Giuily N., Boyer N., and Marcellin P. The current status of antiviral therapy of chronic hepatitis B. J Clin Virol 34 Suppl. 1 (2005) S115-S124
11. Marcellin P., Castelnau C., Martinot-Peignoux M., and Boyer N. Natural history of hepatitis B. Minerva Gastroenterol Dietol 51 (2005) 63-75
12. Zarski J.P., Marcellin P., Leroy V., Trepo C., Samuel D., Ganne-Carrie N., et al. Characteristics of patients with chronic hepatitis B in France: Predominant frequency of HBe antigen negative cases. J Hepatol 45 (2006) 355-360
13. Terrault N., Kim R., Schalm S., Lim S.G., Papatheodoridis G., Alberti A., et al. [483] Presence of biopsy-proven histologic damage (necroinflammation and fibrosis) is common even when ALT is less than 2X ULN in patients with chronic hepatitis B (CHB) (abstract). J Hepatol 46 (2007) S184
14. Bedossa P., Dargere D., and Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38 (2003) 1449-1457
15. Chen C.J., Yang H.I., Su J., Jen C.L., You S.L., Lu S.N., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (2006) 65-73
16. Brook M.G., Karayiannis P., and Thomas H.C. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 10 (1989) 761-763
17. Perrillo R.P., Schiff E.R., Davis G.L., Bodenheimer Jr. H.C., Lindsay K., Payne J., et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med 323 (1990) 295-301
18. Lok A.S., Wu P.C., Lai C.L., Lau J.Y., Leung E.K., Wong L.S., et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 102 (1992) 2091-2097
19. Thomas H., Foster G., and Platis D. Mechanisms of action of interferon and nucleoside analogues. J Hepatol 39 Suppl. 1 (2003) S93-S98
20. Brunetto M.R., Oliveri F., Coco B., Leandro G., Colombatto P., Gorin J.M., et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 36 (2002) 263-270
21. Niederau C., Heintges T., Lange S., Goldmann G., Niederau C.M., Mohr L., et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 334 (1996) 1422-1427
22. Fattovich G., Giustina G., Realdi G., Corrocher R., Schalm S.W., Degos F., et al. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Hepatology 26 (1997) 1338-1342
23. Lau D.T., Everhart J., Kleiner D.E., Park Y., Vergalla J., Schmid P., et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 113 (1997) 1660-1667
24. Lok A.S., Chung H.T., Liu V.W., and Ma O.C. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 105 (1993) 1833-1838
25. Krogsgaard K. The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP). Executive Team on Anti-Viral Treatment. J Viral Hepat 5 (1998) 389-397
26. Korenman J., Baker B., Waggoner J., Everhart J.E., Di Bisceglie A.M., and Hoofnagle J.H. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 114 (1991) 629-634
27. Marcellin P., Martinot-Peignoux M., Loriot M.A., Giostra E., Boyer N., Thiers V., et al. Persistence of hepatitis B virus DNA demonstrated by polymerase chain reaction in serum and liver after loss of HBsAg induced by antiviral therapy. Ann Intern Med 112 (1990) 227-228
28. Loriot M.A., Marcellin P., Bismuth E., Martinot-Peignoux M., Boyer N., Degott C., et al. Demonstration of hepatitis B virus DNA by polymerase chain reaction in the serum and the liver after spontaneous or therapeutically induced HBeAg to anti-HBe or HBsAg to anti-HBs seroconversion in patients with chronic hepatitis B. Hepatology 15 (1992) 32-36
29. Lampertico P., Del Ninno E., Manzin A., Donato M.F., Rumi M.G., Lunghi G., et al. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 26 (1997) 1621-1625
30. Fattovich G., Farci P., Rugge M., Brollo L., Mandas A., Pontisso P., et al. A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg. Hepatology 15 (1992) 584-589
31. Hadziyannis S., Bramou T., Makris A., Moussoulis G., Zignego L., and Papaioannou C. Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B. J Hepatol 11 Suppl. 1 (1990) S133-S136
32. Pastore G., Santantonio T., Milella M., Monno L., Mariano N., Moschetta R., et al. Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon. J Hepatol 14 (1992) 221-225
33. Papatheodoridis G.V., Manesis E., and Hadziyannis S.J. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 34 (2001) 306-313
34. Lampertico P., Del Ninno E., Vigano M., Romeo R., Donato M.F., Sablon E., et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 37 (2003) 756-763
35. Chan H.L., Leung N.W., Hui A.Y., Wong V.W., Liew C.T., Chim A.M., et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 142 (2005) 240-250
36. Marcellin P., Lau G.K., Bonino F., Farci P., Hadziyannis S., Jin R., et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351 (2004) 1206-1217
37. Marcellin P., Bonino F., Lau O.K., Farci P., Yurdaydin C., Piratvisuth T., et al. Virological and biochimical response in patients with HBeAg-negative CHB treated with Peginterferon a-2a (40 kD) +/- Lamivudine: 3-year follow-up results (abstract). J Hepatol 46 (2007) S25-S26
38. Schalm S.W., Heathcote J., Cianciara J., Farrell G., Sherman M., Willems B., et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 46 (2000) 562-568
39. Flink H.J., van Zonneveld M., Hansen B.E., de Man R.A., Schalm S.W., and Janssen H.L. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 101 (2006) 297-303
40. Wai C.T., Chu C.J., Hussain M., and Lok A.S. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 36 (2002) 1425-1430
41. Nicoll A., and Locarnini S. Review: present and future directions in the treatment of chronic hepatitis B infection. J Gastroenterol Hepatol 12 (1997) 843-854
42. Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res 64 (2004) 1-15
43. Lai C.L., Chien R.N., Leung N.W., Chang T.T., Guan R., Tai D.I., et al. A 1-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 339 (1998) 61-68
44. Dienstag J.L., Perrillo R.P., Schiff E.R., Bartholomew M., Vicary C., and Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 333 (1995) 1657-1661
45. Liaw Y.F., Leung N.W., Chang T.T., Guan R., Tai D.I., Ng K.Y., et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 119 (2000) 172-180
46. Leung N.W., Lai C.L., Chang T.T., Guan R., Lee C.M., Ng K.Y., et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 33 (2001) 1527-1532
47. Chang T.T., Lai C.L., Chien R.N., Guan R., Lim S.G., Lee C.M., et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 19 (2004) 1276-1282
48. Lok A.S., Hussain M., Cursano C., Margotti M., Gramenzi A., Grazi G.L., et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 32 (2000) 1145-1153
49. Hadziyannis S.J., Papatheodoridis G.V., Dimou E., Laras A., and Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 32 (2000) 847-851
50. Lau D.T., Khokhar M.F., Doo E., Ghany M.G., Herion D., Park Y., et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 32 (2000) 828-834
51. Tassopoulos N.C., Volpes R., Pastore G., Heathcote J., Buti M., Goldin R.D., et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 29 (1999) 889-896
52. Santantonio T., Mazzola M., Iacovazzi T., Miglietta A., Guastadisegni A., and Pastore G. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 32 (2000) 300-306
53. Rizzetto M., Volpes R., and Smedile A. Response of pre-core mutant chronic hepatitis B infection to lamivudine. J Med Virol 61 (2000) 398-402
54. Papatheodoridis G.V., Dimou E., Laras A., Papadimitropoulos V., and Hadziyannis S.J. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 36 (2002) 219-226
55. Samuel D. Management of hepatitis B in liver transplantation patients. Semin Liver Dis 24 Suppl. 1 (2004) 55-62
56. Papatheodoridis G.V., Dimou E., Dimakopoulos K., Manolakopoulos S., Rapti I., Kitis G., et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 42 (2005) 121-129
57. Liaw Y.F., Sung J.J., Chow W.C., Farrell G., Lee C.Z., Yuen H., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
58. Dienstag J.L., Schiff E.R., Wright T.L., Perrillo R.P., Hann H.W., Goodman Z., et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341 (1999) 1256-1263
59. Lok A.S., Lai C.L., Leung N., Yao G.B., Cui Z.Y., Schiff E.R., et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125 (2003) 1714-1722
60. Liaw Y.F., Chien R.N., Yeh C.T., Tsai S.L., and Chu C.M. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 30 (1999) 567-572
61. Bartholomeusz M.M., Jansen R.W., Jeffers L.J., Reddy K.R., Johnson L.C., Bunzendahl H., et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 349 (1997) 20-22
62. Yuen M.F., Sablon E., Hui C.K., Yuan H.J., Decraemer H., and Lai C.L. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 34 (2001) 785-791
63. Marcellin P., Chang T.T., Lim S.G., Tong M.J., Sievert W., Shiffman M.L., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348 (2003) 808-816
64. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 348 (2003) 800-807
65. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131 (2006) 1743-1751
66. Perrillo R., Hann H.W., Mutimer D., Willems B., Leung N., Lee W.M., et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 126 (2004) 81-90
67. Schiff E.R., Lai C.L., Hadziyannis S., Neuhaus P., Terrault N., Colombo M., et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 38 (2003) 1419-1427
68. Schiff E., Lai C.L., Hadziyannis S., Neuhaus P., Terrault N., Colombo M., et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 13 (2007) 349-360
69. Benhamou Y., Bochet M., Thibault V., Calvez V., Fievet M.H., Vig P., et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 358 (2001) 718-723
70. Benhamou Y., Fleury H., Trimoulet P., Pellegrin I., Urbinelli R., Katlama C., et al. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology 43 (2006) 548-555
71. Marcellin P., and Asselah T. Resistance to adefovir: a new challenge in the treatment of chronic hepatitis B. J Hepatol 43 (2005) 920-923
72. Fung S.K., Chae H.B., Fontana R.J., Conjeevaram H., Marrero J., Oberhelman K., et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 44 (2006) 283-290
73. Fung S.K., Andreone P., Han S.H., Rajender Reddy K., Regev A., Keeffe E.B., et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 43 (2005) 937-943
74. Lee Y.S., Suh D.J., Lim Y.S., Jung S.W., Kim K.M., Lee H.C., et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 43 (2006) 1385-1391
75. Lampertico P., Vigano M., Manenti E., Iavarone M., Sablon E., and Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 133 (2007) 1445-1451
76. Schildgen O., Sirma H., Funk A., Olotu C., Wend U.C., Hartmann H., et al. Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 354 (2006) 1807-1812
77. Durantel D., Carrouee-Durantel S., Werle-Lapostolle B., Brunelle M.N., Pichoud C., Trepo C., et al. A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus. Hepatology 40 (2004) 855-864
78. Chang T.T., Gish R.G., de Man R., Gadano A., Sollano J., Chao Y.C., et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354 (2006) 1001-1010
79. Gish R.G., Lok A.S., Chang T.-T., de Man R.A., Gadano A., Sollano J., et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 133 (2007) 1437-1444
80. Chang T.T., Gish R.G., Hadziyannis S.J., Cianciara J., Rizzetto M., Schiff E.R., et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology 129 (2005) 1198-1209
81. Lai C.L., Shouval D., Lok A.S., Chang T.T., Cheinquer H., Goodman Z., et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354 (2006) 1011-1020
82. Sherman M., Yurdaydin C., Sollano J., Silva M., Liaw Y.F., Cianciara J., et al. Entecavir for treatment of lamivudine-refractory. HBeAg-positive chronic hepatitis B. Gastroenterology 130 (2006) 2039-2049
83. Villeneuve J.P., Durantel D., Durantel S., Westland C., Xiong S., Brosgart C.L., et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 39 (2003) 1085-1089
84. Colonno R.J., Rose R., Baldick C.J., Levine S., Pokornowski K., Yu C.F., et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 44 (2006) 1656-1665
85. Colonno R.T., Rose R.E., Pokornowski K., Baldick C.T., Eggers B., Yu D., et al. Four years assessment of ETV resistance in nucleoside-naive and lamivudine refractory patients (abstract). J Hepatol 46 (2007) S294
86. Tenney D.J., Rose R.E., Baldick C.J., Levine S.M., Pokornowski K.A., Walsh A.W., et al. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 51 (2007) 902-911
87. Zhou X.J., Lim S.G., Lloyd D.M., Chao G.C., Brown N.A., and Lai C.L. Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacodynamic implications. Antimicrob Agents Chemother 50 (2006) 874-879
88. Yuen M.F., and Lai C.L. Telbivudine: an upcoming agent for chronic hepatitis B. Expert Rev Anti Infect Ther 3 (2005) 489-494
89. Lai C.L., Gane E., Liaw Y.F., Hsu C.W., Thongsawat S., Wang Y., et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 357 (2007) 2576-2588
90. Hou J., Yin Y.K., Xu D., Tan D., Niu J., Zhou X., et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology 47 (2008) 447-454
91. Lai C.L., Leung N., Teo E.K., Tong M., Wong F., Hann H.W., et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129 (2005) 528-536
92. Chan H.L., Heathcote E.J., Marcellin P., Lai C.L., Cho M., Moon Y.M., et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 147 (2007) 745-754
93. Lai C.L., Gane E., Hsu C.-W., Thongsawat S., Wang Y., Chen Y., et al. Two-year results from the Globe trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LDT) vs lamivudine (abstract). Hepatology 44 (2006) 222A
94. Heathcote J., George J., Gordon S., Bronowicki J.P., Sperl J., Williams R., et al. Tenofovir Disoproxil Fumarate (TDF) for the treatment of HBeAg-positive chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (Study 103) (abstract). J Hepatol 48 (2008) S32
95. Marcellin P., Jacobson I., Habersetzer F., Senturk H., Andreone P., Moyes C., et al. Tenofovir Disoproxil Fumarate (TDF) for the treatment of HBeAg-negative chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (Study 102) (abstract). J Hepatol 48 (2008) S26
96. Ristig M.B., Crippin J., Aberg J.A., Powderly W.G., Lisker-Melman M., Kessels L., et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis 186 (2002) 1844-1847
97. Benhamou Y., and Poynard T. Treatment of chronic hepatitis B virus infection in patients co-infected with human immunodeficiency virus. J Hepatol 39 Suppl 1 (2003) S194-S199
98. Peters M.G., Andersen J., Lynch P., Liu T., Alston-Smith B., Brosgart C.L., et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 44 (2006) 1110-1116
99. Dore G.J., Cooper D.A., Pozniak A.L., DeJesus E., Zhong L., Miller M.D., et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 189 (2004) 1185-1192
100. Kuo A., Dienstag J.L., and Chung R.T. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol 2 (2004) 266-272
101. Van Bommel F., Wunsche T., Mauss S., Reinke P., Bergk A., Schurmann D., et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 40 (2004) 1421-1425
102. Van Bommel F., Schernick A., Hopf U., and Berg T. Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation. Gastroenterology 124 (2003) 586-587
103. Van Bommel F., Zollner B., Sarrazin C., Spengler U., Huppe D., Moller B., et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 44 (2006) 318-325
104. Ying C., De Clercq E., Nicholson W., Furman P., and Neyts J. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. J Viral Hepat 7 (2000) 161-165
105. Durantel D., Brunelle M.N., Gros E., Carrouee-Durantel S., Pichoud C., Villet S., et al. Resistance of human hepatitis B virus to reverse transcriptase inhibitors: from genotypic to phenotypic testing. J Clin Virol 34 Suppl. 1 (2005) S34-S43
106. Lada O., Benhamou Y., Cahour A., Katlama C., Poynard T., and Thibault V. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir Ther 9 (2004) 353-363
107. Lim S.G., Krastev Z., Ng T.M., Mechkov G., Kotzev I.A., Chan S., et al. Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B. Antimicrob Agents Chemother 50 (2006) 1642-1648
108. Marcellin P., Mommeja-Marin H., Sacks S.L., Lau G.K., Sereni D., Bronowicki J.P., et al. A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology 40 (2004) 140-148
109. Yoo B.C., Kim J.H., Chung Y.H., Lee K.S., Paik S.W., Ryu S.H., et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 45 (2007) 1172-1178
110. Yoo B.C., Kim J.H., Kim T.H., Koh K.C., Um S.H., Kim Y.S., et al. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology 46 (2007) 1041-1048
111. Lim S.G., Leung N., Hann H.W., Lau G.K., Trepo C., Mommeja-Marin H., et al. Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti-viral activity of clevudine for 12 weeks in patients with chronic hepatitis B. Aliment Pharmacol Ther 27 (2008) 1282-1292
112. Locarnini S., Hatzakis A., Heathcote J., Keeffe E.B., Liang T.J., Mutimer D., et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 9 (2004) 679-693
113. Fares M.A., and Holmes E.C. A revised evolutionary history of hepatitis B virus (HBV). J Mol Evol 54 (2002) 807-814
114. Park S.G., Kim Y., Park E., Ryu H.M., and Jung G. Fidelity of hepatitis B virus polymerase. Eur J Biochem 270 (2003) 2929-2936
115. Das K., Xiong X., Yang H., Westland C.E., Gibbs C.S., Sarafianos S.G., et al. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol 75 (2001) 4771-4779
116. Bartholomeusz A., Tehan B.G., and Chalmers D.K. Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations. Antivir Ther 9 (2004) 149-160
117. Lai C.L., Ratziu V., Yuen M.F., and Poynard T. Viral hepatitis B. Lancet 362 (2003) 2089-2094
118. Nafa S., Ahmed S., Tavan D., Pichoud C., Berby F., Stuyver L., et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 32 (2000) 1078-1088
119. Zoulim F. Antiviral therapy of chronic hepatitis B: can we clear the virus and prevent drug resistance?. Antivir Chem Chemother 15 (2004) 299-305
120. Tenney D.J., Levine S.M., Rose R.E., Walsh A.W., Weinheimer S.P., Discotto L., et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 48 (2004) 3498-3507
121. Langley D.R., Walsh A.W., Baldick C.J., Eggers B.J., Rose R.E., Levine S.M., et al. Inhibition of hepatitis B virus polymerase by entecavir. J Virol 81 (2007) 3992-4001
122. Angus P., Vaughan R., Xiong S., Yang H., Delaney W., Gibbs C., et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125 (2003) 292-297
123. Curtis M., Zhu Y., and Borroto-Esoda K. Hepatitis B virus containing the I233V mutation in the polymerase reverse-transcriptase domain remains sensitive to inhibition by adefovir. J Infect Dis 196 (2007) 1483-1486
124. Sheldon J., Camino N., Rodes B., Bartholomeusz A., Kuiper M., Tacke F., et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 10 (2005) 727-734
125. Piccolo P., Lend I., Di Paolo D., Telesca C., DeMelia L., Sorbello O., et al. [54] Peginterferon-alpha-2a plus adefovir vs. peginterferon-alpha-2a for 48 weeks in HBeAg-negative chronic hepatitis B: preliminary 24-week results of the Peg for B randomozed multicenter trial (abstract). J Hepatol 46 (2007) S26
126. Sung J.J.Y., Lai J.Y., Zeuzem S., Chow W.C., Heathcote E., Perrillo R., et al. A randomised double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipovoxil (ADV) for treatment naive patients with chronic hepatitis B (CHB): Week 52 analysis. J Hepatol 38 Suppl. 2 (2003) 25-26
127. Lau G.K., Tsiang M., Hou J., Yuen S.-T., Carman W.-F., Zhang L., et al. Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study. Hepatology 32 (2000) 394-399
128. Peters M.G., Hann Hw H., Martin P., Heathcote E.J., Buggisch P., Rubin R., et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 126 (2004) 91-101
129. Lampertico P., Marzano A., Levrero M., Santantonio T., Di Marco V., Brunette M., et al. [502] Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patient with HBe Ag-negative chronic hepatitis B (abstract). J Hepatol 46 (2007) S191
130. Rapti I., Dimou E., Mitsoula P., and Hadziyannis S.J. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 45 (2007) 307-313